丙型肝炎病毒相关失代偿期肝硬化病因治愈后的再代偿:美国退伍军人研究
该回顾性队列研究基于美国退伍军人丙肝相关失代偿期肝硬化患者,评估直接抗病毒药物获得持续病毒学应答后再代偿的频率、预测因素及预后意义。1213例患者中13%在启动治疗后24个月内达到Baveno VII再代偿,再代偿与全因死亡风险降低相关,基线白蛋白较高预测再代偿,血小板<110×10^9/L和进一步失代偿降低再代偿可能。
要点
- HCV相关失代偿期肝硬化治愈后约13%患者可实现再代偿。
- 再代偿与后续全因死亡风险降低相关。
- 基线白蛋白较高预测再代偿,血小板<110×10^9/L和进一步失代偿降低再代偿可能。
核心结论
- HCV相关失代偿期肝硬化患者获得持续病毒学应答后,有相当比例可实现再代偿,且再代偿与生存改善相关。
- 肝脏合成功能保留较好且门脉高压较轻者更可能再代偿,而进一步失代偿降低再代偿可能。
- 腹水消退单独即可识别大多数达到Baveno VII再代偿的患者,提示其可作为再代偿的实用临床标志物。
研究设计与样本
- 回顾性队列研究,使用退伍军人肝病结局与费用(VOCAL)队列。
- 纳入HCV相关肝硬化、直接抗病毒治疗前影像学证实腹水且获得持续病毒学应答的患者。
- 共1213例 eligible 患者纳入分析。
- 主要结局为随访期间按Baveno VII标准定义的再代偿。
- 采用Fine-Gray回归分析再代偿预测因素,以死亡或肝移植为竞争事件;24个月landmark分析评估后续全因死亡(Cox回归)和肝细胞癌(Fine-Gray回归);另用Fine-Gray分析评估腹水消退时间。
主要发现
- 1213例患者中163例(13%)在直接抗病毒治疗启动后24个月内达到再代偿。
- 多因素分析中,基线白蛋白较高独立预测再代偿。
- 血小板计数<110×10^9/L和进一步失代偿与再代偿可能性降低相关。
- 再代偿与后续全因死亡风险降低相关。
- 腹水消退的预测因素与再代偿的预测因素相似。
关键数值与推荐
- 再代偿定义采用Baveno VII标准。
- 血小板计数<110×10^9/L与再代偿可能性降低相关。
- 再代偿评估时间窗为直接抗病毒治疗启动后24个月内。
临床怎么用
- 对HCV相关失代偿期肝硬化患者,达到持续病毒学应答后应关注再代偿可能,尤其基线白蛋白较高、血小板≥110×10^9/L且无进一步失代偿者。
- 腹水消退可作为临床实践中识别再代偿的实用标志。
- 再代偿与生存改善相关,提示应积极管理门脉高压并发症并监测病情变化。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Recompensation after etiologic cure is increasingly recognized as an achievable state in decompensated cirrhosis, but United States data remain limited. We evaluated the frequency, predictors, and prognostic relevance of recompensation after hepatitis C virus (HCV) cure in United States Veterans with HCV-related decompensated cirrhosis. METHODS: We performed a retrospective cohort study using the Veterans Outcomes and Costs Associated with Liver Disease (VOCAL) cohort. Patients with HCV-related cirrhosis, imaging-documented ascites before direct-acting antiviral therapy, and sustained virologic response were included. The primary outcome was recompensation (per Baveno VII criteria) during follow-up. Fine-Gray regression was used for univariable and multivariable analyses of predictors of recompensation, with death or liver transplantation as competing events. A 24-month landmark analysis assessed subsequent all-cause mortality (Cox regression) and hepatocellular carcinoma (Fine-Gray regression). A separate Fine-Gray analysis evaluated time to documented ascites resolution. RESULTS: Among 1213 eligible patients, 163 (13%) achieved recompensation up to 24 months after direct-acting antiviral initiation. In multivariable analysis, higher baseline albumin independently predicted recompensation, whereas platelet count <110 × 109/L and further decompensation were associated with a lower likelihood of recompensation. Recompensation was associated with reduced subsequent all-cause mortality. Predictors of documented ascites resolution were similar to those of recompensation. CONCLUSIONS: Recompensation occurs in a meaningful proportion of patients with HCV-related decompensated cirrhosis after sustained virologic response and is associated with improved survival. Patients with preserved liver synthetic function and less severe portal hypertension are more likely to recompensate, whereas further decompensation reduces this likelihood. Ascites resolution alone identified most patients achieving Baveno VII-defined recompensation, suggesting it may serve as a pragmatic clinical marker of recompensation.
引用
- Goyes D, Rabiee A, Chong-Lugon N, et al. Recompensation After Etiologic Cure in United States Veterans With Hepatitis C Virus-Related Decompensated Cirrhosis. Clin Gastroenterol Hepatol. 2026. PMID: 42637171. doi:10.1016/j.cgh.2026.08.010
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。